 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine
"2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A selective D1 dopamine receptor agonist used primarily as a research tool.
| Descriptor ID |
D015647
|
| MeSH Number(s) |
D03.438.079.800
|
| Concept/Terms |
2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine- 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine
- 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-1-phenyl-
SK&F-38393- SK&F-38393
- SK&F 38393
- SK&F38393
- SKF-38393
- SKF 38393
- R-SK&F 38393
- RSK&F 38393
- SKF 38393-A
- SKF 38393 A
- SKF 38393A
- SKF38393
|
Below are MeSH descriptors whose meaning is more general than "2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine".
Below are MeSH descriptors whose meaning is more specific than "2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine".
This graph shows the total number of publications written about "2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine" by people in this website by year, and whether "2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1990 | 1 | 1 | 2 | | 1991 | 1 | 0 | 1 | | 1992 | 1 | 0 | 1 | | 1993 | 1 | 0 | 1 | | 2001 | 0 | 1 | 1 | | 2008 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine" by people in Profiles.
-
Hu XT, Nasif FJ, Zhang J, Xu M. Fos regulates neuronal activity in the nucleus accumbens. Neurosci Lett. 2008 Dec 19; 448(1):157-60.
-
Kim JH, Perugini M, Austin JD, Vezina P. Previous exposure to amphetamine enhances the subsequent locomotor response to a D1 dopamine receptor agonist when glutamate reuptake is inhibited. J Neurosci. 2001 Mar 01; 21(5):RC133.
-
Cravchik A, Gejman PV. Functional analysis of the human D5 dopamine receptor missense and nonsense variants: differences in dopamine binding affinities. Pharmacogenetics. 1999 Apr; 9(2):199-206.
-
Shusterman NH, Elliott WJ, White WB. Fenoldopam, but not nitroprusside, improves renal function in severely hypertensive patients with impaired renal function. Am J Med. 1993 Aug; 95(2):161-8.
-
Gretler DD, Elliott WJ, Moscucci M, Childers RW, Murphy MB. Electrocardiographic changes during acute treatment of hypertensive emergencies with sodium nitroprusside or fenoldopam. Arch Intern Med. 1992 Dec; 152(12):2445-8.
-
Elliott WJ, Karnezis TA, Silverman RA, Geanon J, Tripathi RC, Murphy MB. Intraocular pressure increases with fenoldopam, but not nitroprusside, in hypertensive humans. Clin Pharmacol Ther. 1991 Mar; 49(3):285-93.
-
Elliott WJ, Weber RR, Nelson KS, Oliner CM, Fumo MT, Gretler DD, McCray GR, Murphy MB. Renal and hemodynamic effects of intravenous fenoldopam versus nitroprusside in severe hypertension. Circulation. 1990 Mar; 81(3):970-7.
-
Murphy MB, Elliott WJ. Dopamine and dopamine receptor agonists in cardiovascular therapy. Crit Care Med. 1990 Jan; 18(1 Pt 2):S14-8.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|